Herzuma is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC):...in combination with paclitaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease and for whom an anthracycline is not suitable....in combination with docetaxel for the treatment of those patients who have not received chemotherapy for their metastatic disease….in combination with adjuvant chemotherapy consisting of docetaxel and carboplatin….in combination with neoadjuvant chemotherapy followed by adjuvant Herzuma therapy, for locally advanced (including inflammatory) disease or tumours > 2 cm in diameter....Herzuma should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.

Herzuma is indicated for the treatment of adult patients with HER2 positive metastatic breast cancer (MBC):...as monotherapy for the treatment of those patients who have received at least two chemotherapy regimens for their metastatic disease….Herzuma should only be used in patients with metastatic or early breast cancer whose tumours have either HER2 overexpression or HER2 gene amplification as determined by an accurate and validated assay.

549 patients with HER2+ EBC were randomized to receive C (n=271) or trastuzumab (n=278) in combination with docetaxel (Cycles 1-4) and 5-fluorouracil, epirubicin, and cyclophosphamide (Cycles 5-8)….pCR rate was 46.8% for C and 50.4% for trastuzumab….study demonstrated the similarity of efficacy in terms of pCR between CT-P6 and trastuzumab in EBC patients.